Compare Sanofi SA (SNY) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs BlackRock TCP Capital Corp — how do they compare? Sanofi SA trades at $40.11 (market cap $95.18B), while BlackRock TCP Capital Corp trades at $4.03 (market cap $337.71M). The key difference: Sanofi SA is far larger — about 281.8× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.88%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and BlackRock TCP Capital Corp for 88 Days on average.
| SNY | TCPC | |
|---|---|---|
Market Cap | $95.18B | $337.71M |
Volume | 2,995,646 | 436,109 |
Sector | Health | Financials |
52-Week High | $52.34 | $6.20 |
52-Week Low | $39.51 | $3.13 |
Typical Hold Time | 94 Days | 88 Days |
Enterprise Value | $114.48B | $1.09B |
Dividend Yield | 6.01% | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
TCPC trades at $4.035, up 2.41% today, with a bullish technical signal supported by moving averages. The company reported mixed earnings with Q2 2026 beating estimates but faces negative revenue and net income trends. Recent portfolio sales and strategic reviews aim to reduce leverage and enhance shareholder value. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
Outlook remains cautious due to declining revenue and negative profitability metrics, though strategic moves may stabilize operations. Key risks include ongoing financial losses and competitive pressures in the BDC sector. Investment opportunity hinges on successful execution of portfolio optimization and debt reduction initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
